Gilead stock down nearly 4% as drug trial fizzles
Gilead Sciences Inc. GILD, +0.22% shares fell 4% in the extended session Monday after the pharma company said a late-stage, placebo-controlled study designed to evaluate a type of chronic liver disease drug, Selonsertib, did not meet its desired outcome without worsening the patients’ condition. "While we are disappointed that the STELLAR-4 study did not achieve its primary endpoint, we remain committed to advancing therapies for patients with advanced fibrosis due to (nonalcoholic steatohepatitis), where there is a significant unmet need for effective and well-tolerated treatments," the company said in a statement. Data collected in this study "will further advance our understanding of the disease," Gilead said. Gilead had ended the regular trading day up 0.2%.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
Source: Read Full Article